Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03497767
Title A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)
Acronym OUTRUN
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Trans Tasman Radiation Oncology Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.